Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 85Lymphoma, Follicular 18Recurrence 11Lymphoma, Large B-Cell, Diffuse 11Neoplasms, Plasma Cell 8Lymphoma 7Lymphoma, B-Cell, Marginal Zone 6Lymphoma, Non-Hodgkin 5Neoplasms 4Lymphoma, Mantle-Cell 4Hematologic Diseases 4Smoldering Multiple Myeloma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Disease Progression 3Paraproteinemias 2Myelodysplastic Syndromes 2Disease 2Anemia 2Sezary Syndrome 1Prostatic Neoplasms 1Polycythemia Vera 1Plasmacytoma 1Neoplasm Metastasis 1Mycosis Fungoides 1Melanoma 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Cutaneous 1Limb-girdle muscular dystrophy, type 2C 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

Magnetic Resonance Spectroscopy 3Prednisone 2Positron-Emission Tomography 2Lenalidomide 2Injections 2Dexamethasone 2Cyclophosphamide 2technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid) 1obinutuzumab 1lortalamine 1fluciclovine F-18 1Vindesine 1Vincristine 1Transplantation, Autologous 1Thalidomide 1Rituximab 1Mitomycin 1Melphalan 1Doxorubicin 1Diagnosis 1Bleomycin 13-Iodobenzylguanidine 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Disease × Lenalidomide × Clear all
NCT01093196 2024-11-07

Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients

Fondazione EMN Italy Onlus

Phase 3 Completed
660 enrolled
Plasma cell

Disease, Multiple Myeloma

NCT02215980 2024-07-22

STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS

Fondazione EMN Italy Onlus

Phase 3 Completed
210 enrolled
Plasma cell

Disease, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡